The South Bend Clinic Center for Research

South Bend, Indiana 56617

1 studies enrolling now · 12 studies all time

What they study most

Alopecia, Alopecia Areata, Areata Alopecia, Atopic Dermatitis, Dermatitis, Atopic, Hair Diseases, Hypotrichosis, Lower Respiratory Tract Disease, Meningococcal Vaccine, Obesity, Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19, Pathological Conditions, Anatomical

Studies at this site

• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata — Recruiting now
• A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation — Running, not enrolling
• A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata — Completed
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — Completed
• A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older — Completed
• A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults — Completed
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency — Completed
• MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age — Completed
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) — Stopped early
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy — Completed
• JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis — Completed